Healthcare Equipment and Services laboratory equipment and services

United States Quest Tender

📄 Tender ID: 455514618 📅 Published: 05 Aug 2020

📋 Tender Overview

A new innovation in advanced genetic sequencing automation from Quest Diagnostics NYSE DGX will now enable individuals to access highly accurate genetic testing providing insights into inherited diseases including cancers of the breast colon and other conditions through AncestryHealth.Quest developed a faster and cheaper way to perform next generation sequencing NGS to power AncestryHealth a new consumer genetics offering launched by Ancestry on August 3. AncestryHealth provides genetic screening of risks for an expanded set of health conditions - such as heart disease breast cancer colon cancer and blood disorders. AncestryHealth powered by NGS looks at more regions in a persons genome than microarray-based testing technology. This improvement in automating next generation sequencing will enable genetic screening faster and at much lower cost and could have profound implications for healthcare in the future truly empowering better health through actionable insights for millions of people who want to know more about their health risks said Steve Rusckowski Chairman Chief Executive and President Quest Diagnostics. The improvements our scientists have made in quality and productivity represent a step change for genetic testing. It wasnt long ago that genetic sequencing took months and cost thousands of dollars. Quests proprietary innovation enables sequencing insights in a fraction of the time at a fraction of the cost.The new technology platform developed at Quests Advanced Diagnostics Research and Development centers in San Juan Capistrano Calif. and Marlborough Mass. combines advancements at every stage of the process including sample miniaturization lab automation and state-of-the-art sequencing and bioinformatics pipelines. The launch marks a dramatic shift in consumer-initiated genetic testing which for the last decade has largely been based on microarray technology. Because NGS technology can access orders of magnitude more of the genome including challenging-to-sequence variants the NGS technology that powers AncestryHealth does a better job of determining if someone is at greater risk for some of the most common inherited health conditions.When it comes to your health and your familys health the more you know the better said Ron Park MD EVP of Health and DNA at Ancestry. Through Ancestrys collaboration with Quest Diagnostics we are able to expand access to valuable genetic health screening information at a time when health is top of mind for everyone.Quest is providing the technology for use in AncestryHealth and AncestryDNA offerings under an exclusive agreement. Additional details of the agreement were not disclosed. Quest has supported AncestryDNA since 2017 using microarray technology at its Advanced Diagnostics Center of Excellence in Marlborough Massachusetts.AncestryHealth powered by NGS can achieve about 80-90 percent detection of inherited risk for specific health conditions.1 For breast and ovarian cancer for example this means the NGS technology powering AncestryHealth has a risk detection rate four times higher than most microarray-based tests. About AncestryHealthIn 2019 Ancestry launched AncestryHealth to empower people to take proactive steps in collaboration with their healthcare provider to address potential health risks identified in their genes and family health history. The tests offered by AncestryHealth are physician-ordered and are not diagnostic. The tests are not reviewed or approved by the FDA and are not available in NY NJ or RI. About COVID-19 Testing at Quest DiagnosticsQuest Diagnostics isat the forefront of the response to the COVID-19 pandemic working to broaden access to laboratory insights to help us all lead healthier lives. We providebothmolecular diagnostic and antibodyserologytests toaid inthe diagnosis of COVID-19 andimmune response.OurCOVID-19 test servicesare based onteststhathave received FDA emergency use authorizationand whichalsomeet our high standards for quality.We are providing these test services under the Public Readiness and Emergency Preparedness Act. We providedata onCOVID-19testingto various federal and state public health authorities including the Centers for Disease Control and Prevention and participate in studies with government and private institutionsaidingCOVID-19public healthresponseand research.Throughour team ofdedicatedphlebotomists air fleet team couriers andlaboratory professionals Quest Diagnosticsworks hard every day to help patients and communities across the United States access qualityCOVID-19 testing.

🔍 Key Information

📄
Tender Reference No.
455514618
📅
Publication Date
05 Aug 2020
🌐
Sector
Healthcare Equipment and Services
📝
Notice Type
News
📍
Location
United states

📁 Documents & Downloads

No documents found

🏷️ CPV

No CPV found

Need help with this bid?

Our bid experts can help you find, evaluate & win more tenders.

🎧 Talk to Bid Expert
🕒 Submission deadline
0
days remaining · 05 Aug 2020
🔔 Set Alert

🧭 Quick Facts

Authority N/A
Country United states
State / UT N/A
Tender Type Procurement News
Currency N/A
Similar Tenders
Loading similar tenders…